299 related articles for article (PubMed ID: 27380557)
1. Antithrombotic potential of the contact activation pathway.
Schmaier AH
Curr Opin Hematol; 2016 Sep; 23(5):445-52. PubMed ID: 27380557
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation.
Kokoye Y; Ivanov I; Cheng Q; Matafonov A; Dickeson SK; Mason S; Sexton DJ; Renné T; McCrae K; Feener EP; Gailani D
Thromb Res; 2016 Apr; 140():118-124. PubMed ID: 26950760
[TBL] [Abstract][Full Text] [Related]
3. A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release.
Steen Burrell KA; Layzer J; Sullenger BA
J Thromb Haemost; 2017 Sep; 15(9):1807-1817. PubMed ID: 28632925
[TBL] [Abstract][Full Text] [Related]
4. The contact activation and kallikrein/kinin systems: pathophysiologic and physiologic activities.
Schmaier AH
J Thromb Haemost; 2016 Jan; 14(1):28-39. PubMed ID: 26565070
[TBL] [Abstract][Full Text] [Related]
5. Physiologic activities of the contact activation system.
Schmaier AH
Thromb Res; 2014 May; 133 Suppl 1(0 1):S41-4. PubMed ID: 24759141
[TBL] [Abstract][Full Text] [Related]
6. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding.
Revenko AS; Gao D; Crosby JR; Bhattacharjee G; Zhao C; May C; Gailani D; Monia BP; MacLeod AR
Blood; 2011 Nov; 118(19):5302-11. PubMed ID: 21821705
[TBL] [Abstract][Full Text] [Related]
7. The plasma kallikrein-kinin system: its evolution from contact activation.
Schmaier AH; McCrae KR
J Thromb Haemost; 2007 Dec; 5(12):2323-9. PubMed ID: 17883591
[TBL] [Abstract][Full Text] [Related]
8. Factor XII in coagulation, inflammation and beyond.
Didiasova M; Wujak L; Schaefer L; Wygrecka M
Cell Signal; 2018 Nov; 51():257-265. PubMed ID: 30118759
[TBL] [Abstract][Full Text] [Related]
9. The levels of factor XIIa generated in human plasma on an electronegative surface are insensitive to wide variation in the concentration of FXII, prekallikrein, high molecular weight kininogen or FXI.
Mitropoulos KA
Thromb Haemost; 1999 Sep; 82(3):1033-40. PubMed ID: 10494760
[TBL] [Abstract][Full Text] [Related]
10. Plasma levels of bradykinin are suppressed in factor XII-deficient mice.
Iwaki T; Castellino FJ
Thromb Haemost; 2006 Jun; 95(6):1003-10. PubMed ID: 16732380
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Factors XI and XII for Prevention of Thrombosis Induced by Artificial Surfaces.
Tillman B; Gailani D
Semin Thromb Hemost; 2018 Feb; 44(1):60-69. PubMed ID: 28898903
[TBL] [Abstract][Full Text] [Related]
12. Polyphosphate, Zn
Wang Y; Ivanov I; Smith SA; Gailani D; Morrissey JH
J Thromb Haemost; 2019 Dec; 17(12):2131-2140. PubMed ID: 31420909
[TBL] [Abstract][Full Text] [Related]
13. Protease activity in single-chain prekallikrein.
Ivanov I; Verhamme IM; Sun MF; Mohammed B; Cheng Q; Matafonov A; Dickeson SK; Joseph K; Kaplan AP; Gailani D
Blood; 2020 Feb; 135(8):558-567. PubMed ID: 31800958
[TBL] [Abstract][Full Text] [Related]
14. Novel anti-thrombotic mechanisms mediated by Mas receptor as result of balanced activities between the kallikrein/kinin and the renin-angiotensin systems.
Fang C; Schmaier AH
Pharmacol Res; 2020 Oct; 160():105096. PubMed ID: 32712319
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological regulation of factor XII activation may be a new target to control pathological coagulation.
Schousboe I
Biochem Pharmacol; 2008 Mar; 75(5):1007-13. PubMed ID: 17996217
[TBL] [Abstract][Full Text] [Related]
16. Plasma levels of factor XII, prekallikrein and high molecular weight kininogen in normal blood donors and patients having suffered venous thrombosis.
Gallimore MJ; Harris SL; Jones DW; Winter M
Thromb Res; 2004; 114(2):91-6. PubMed ID: 15306150
[TBL] [Abstract][Full Text] [Related]
17. Genetic determinants of activity and antigen levels of contact system factors.
Rohmann JL; de Haan HG; Algra A; Vossen CY; Rosendaal FR; Siegerink B
J Thromb Haemost; 2019 Jan; 17(1):157-168. PubMed ID: 30288888
[TBL] [Abstract][Full Text] [Related]
18. Factor XII Activation Promotes Platelet Consumption in the Presence of Bacterial-Type Long-Chain Polyphosphate In Vitro and In Vivo.
Zilberman-Rudenko J; Reitsma SE; Puy C; Rigg RA; Smith SA; Tucker EI; Silasi R; Merkulova A; McCrae KR; Maas C; Urbanus RT; Gailani D; Morrissey JH; Gruber A; Lupu F; Schmaier AH; McCarty OJT
Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1748-1760. PubMed ID: 30354195
[TBL] [Abstract][Full Text] [Related]
19. Histidine-rich glycoprotein binds DNA and RNA and attenuates their capacity to activate the intrinsic coagulation pathway.
Vu TT; Leslie BA; Stafford AR; Zhou J; Fredenburgh JC; Weitz JI
Thromb Haemost; 2016 Jan; 115(1):89-98. PubMed ID: 26354857
[TBL] [Abstract][Full Text] [Related]
20. Factor XII as a Therapeutic Target in Thromboembolic and Inflammatory Diseases.
Nickel KF; Long AT; Fuchs TA; Butler LM; Renné T
Arterioscler Thromb Vasc Biol; 2017 Jan; 37(1):13-20. PubMed ID: 27834692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
